Share on StockTwits

Achillion Pharmaceuticals (NASDAQ:ACHN) was upgraded by analysts at JMP Securities from a “market perform” rating to an “outperform” rating in a research report issued to clients and investors on Tuesday, TheFlyOnTheWall.com reports. The firm currently has a $13.00 price objective on the stock. JMP Securities’ price target would suggest a potential upside of 205.88% from the company’s current price.

Other equities research analysts have also recently issued reports about the stock. Analysts at Edison Investment Research reiterated a “neutral” rating on shares of Achillion Pharmaceuticals in a research note on Thursday, April 24th. Analysts at Maxim Group upgraded shares of Achillion Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, March 24th. They now have a $6.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating and two have assigned a buy rating to the stock. Achillion Pharmaceuticals has a consensus rating of “Hold” and an average target price of $5.68.

Shares of Achillion Pharmaceuticals (NASDAQ:ACHN) opened at 4.25 on Tuesday. Achillion Pharmaceuticals has a 52 week low of $2.26 and a 52 week high of $8.49. The stock’s 50-day moving average is $2.83 and its 200-day moving average is $3.22. The company’s market cap is $411.4 million.

Achillion Pharmaceuticals (NASDAQ:ACHN) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($0.17) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.16) by $0.01. Analysts expect that Achillion Pharmaceuticals will post $-0.78 EPS for the current fiscal year.

Achillion Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases.

The Fly On The Wall

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.